Company Overview of Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc., a preclinical-stage biopharmaceutical company, intends to develop medicines for use in treating human viral diseases. The company focuses on developing inhibitors that target viral replication enzymes and viral replication protein. It is developing antiviral therapeutics for human diseases, including Hepatitis C virus (HCV), Influenza virus, and Norovirus. The company also develops targeted in-house chemical libraries consisting of antiviral compounds of nucleosides, non-nucleoside inhibitors, metal-binding inhibitors, and fragments. In addition, it is developing compounds that inhibit HCV helicase, an enzyme that is essential for hepatitis C viral replication. The co...
1860 Montreal Road
Tucker, GA 30084
Founded in 2007
Key Executives for Cocrystal Pharma, Inc.
Co-Founder, Vice Chairman and Interim Chief Executive Officer
Total Annual Compensation: $133.5K
Co-Founder and President
Total Annual Compensation: $203.6K
General Counsel and Corporate Secretary
Total Annual Compensation: $132.8K
Compensation as of Fiscal Year 2015.
Cocrystal Pharma, Inc. Key Developments
Cocrystal Pharma, Inc. Announces Resignation of Walt A. Linscott as General Counsel and Secretary, Effective March 1, 2017
Feb 16 17
On February 12, 2017, Walt A. Linscott informed the Board of Directors of Cocrystal Pharma, Inc. of his resignation as General Counsel and Secretary of the company, effective March 1, 2017. Mr. Linscott has accepted a position as President, Chief Operating Officer and General Counsel of a start-up biotechnology company.
Cocrystal Pharma, Inc. Announces Resignation of Curtis Dale as Interim Chief Financial Officer
Jan 30 17
Cocrystal Pharma, Inc. announced that Curtis Dale, Interim Chief Financial Officer, tendered his resignation effective immediately on January 24, 2017. The company has initiated a search for a qualified replacement.
Cocrystal Pharma, Inc. Announces Positive Interim Data from an Ongoing Phase 1 Study with CC-31244 for the Treatment of Chronic Hepatitis C Infection
Nov 7 16
Cocrystal Pharma, Inc. announced positive data from a randomized, double-blind Phase Ia/Ib study of CC-31244, a pan-genotypic, potent NS5B non-nucleoside inhibitor (NNI), for the treatment of chronic hepatitis C virus (HCV) infection. The study is designed to evaluate CC-31244's safety/tolerability and pharmacokinetics, including food effect and antiviral activity. The study includes two groups: Group A (single ascending doses, and multiple doses in healthy volunteers), and Group B (multiple doses in HCV infected individuals). The study has dosed a total of 42 healthy volunteers with single (20, 50, 100, 200 and 400 mg) and multiple doses of CC-31244 at 200 and 400 mg for 7 days. Five HCV GT1 infected patients were dosed, four with 400 mg of CC-31244 once daily for 7 days and one with placebo. Data from the once daily 400 mg dosing arm demonstrate that CC-31244 had a substantial and durable antiviral effect with an average HCV RNA viral load decline from baseline of 3 log orders by 48 hours after dosing. The average viral load at 6 days post last dose remained on average 1.9 log orders below baseline. In addition, no viral breakthrough was observed during the treatment period. No serious adverse event was reported. CC-31244 is an investigational, oral, potent, pan-genotypic NNI with high barrier to drug resistance designed and developed using the company's proprietary structure-based drug discovery technology. The molecule interacts with the NS5B RNA polymerase of all major HCV genotypes.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 1, 2016
August 17, 2016
March 14, 2016